Clinical Trial

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Study acronym: ADAPT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-31; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2023-09-14
Trial Details
NCT Number NCT06028828
Lead Sponsor University of California, Irvine
Conditions Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
Enrollment 60 participants
Start Date 2023-09-11
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-02